U.S. Naloxone Market to Surpass US$ 2,909.1 Million by 2030 - Coherent Market Insights

According to Coherent Market Insights,  the U.S. naloxone market is estimated to be valued at US$ 1,390.7 million in 2023 and is expected to exhibit a CAGR of 10.2% during the forecast period (2023-2030).

Naloxone is an opioid antagonist medication that is used for the complete or partial reversal of opioid overdose, including respiratory depression, sedation, and hypotension. It works by blocking the effects of opioids, primarily in the central nervous system and respiratory centers.

Market Dynamics:

The growth of the U.S. naloxone market is mainly driven by the increasing opioid overdose cases leading to excessive demand for naloxone formulations. According to the Center for Disease Control and Prevention (CDC), over 100,000 drug overdose deaths were recorded in the U.S. during a 12-month period ending in April 2021, which marks an increase of around 28.5% from the 78,056 deaths. Additionally, the increasing availability of generic and low-cost naloxone formulations is also contributing to the market growth. Furthermore, growing awareness and educational programs about opioid overdose held by the government and non-profit organizations are further propelling the demand for naloxone products.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4953

Market Driver:

Increased Overdose Deaths Drives the Demand for Naloxone in the U.S. Over the past few years, the U.S. has been facing a drug overdose epidemic with nearly 750,000 Americans dying from an overdose in the last decade alone. Just between 2019-2020, overdose deaths in the U.S. rose by nearly 30%. The increase has been primarily driven by synthetic opioids like fentanyl which has contributed to over 75% of overdose deaths. As more people struggle with addiction and overdose rates remain high, it has increased the demand for overdose reversal drugs like naloxone across the U.S. States and cities are expanding access to naloxone to help save lives through programs that train first responders and make it available without a prescription. 

Market Restraint:

Concerns Over Recreational Use May Deter Wider Distribution. While expanding access to naloxone could help reduce preventable deaths, some argue that it may also discourage those struggling with addiction from seeking long-term treatment. There are concerns that greater availability could enable reckless drug use with the perception that naloxone is readily available to reverse an overdose. Some studies have found an association between increased naloxone access and the use of more dangerous opioid mixtures. This has led to concerns over facilitating recreational opioid use and potential misuse of naloxone kits obtained without a prescription. Concerns over misuse and abuse may deter some states from implementing wide distribution programs of naloxone without medical oversight. 

Purchase of this report @ https://www.coherentmarketinsights.com/insight/buy-now/4953

Market Opportunity:

The Biden administration has taken the opioid overdose crisis very seriously and provided substantial funding to address it. The administration's 2023 budget proposes more than $32 billion to curb overdose deaths over the next decade which is double the previous year's commitment. Billions in federal grants have been committed to helping states tackle the issue through prevention, treatment, harm reduction and recovery programs. A large chunk of funding is proposed specifically for naloxone procurement and distribution through programs like the State Opioid Response Grant initiative. This massive increase in public funding directed at combatting overdoses presents a golden opportunity for companies manufacturing naloxone as demand is set to surge across the U.S. in the coming years. 

Market Trend:

While nasal spray versions of naloxone have helped increase accessibility, there is a gradual shift towards easier to use auto-injector devices. Auto-injectors provide voice instructions to guide users and don't require assembly like Nasal sprays. This reduces errors during administration in chaotic overdose situations. Companies like Pfizer and Adapt Pharma have received FDA approval for their auto-injector naloxone products. Their widespread availability will help expand access beyond just emergency responders and indoor use-cases to wider public settings. Auto-injectors are poised to become the dominant naloxone format in the U.S. in the near future, supported by substantial public procurement programs. This shift in delivery technology is a major market trend that will bolster adoption rates. 

Competitive Landscape

In the segment specifically devoted to leading companies in the U.S. Naloxone Market of the market analysis document, our researchers provide a summary of the financial statements of all the major companies, covering their noteworthy developments, product benchmarking, and SWOT analysis. The corporate profile copy also includes financial information and a business summary. The businesses in this area can be customized to match the unique needs of the client.

Some of the Top Players in U.S. Naloxone Market: 

Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., Kern Pharma, S.L., Samarth Life Sciences Pvt. Ltd., Opiant Pharmaceuticals, Pfizer, Sandoz, and Amneal Pharmaceuticals

Regional Analysis -

North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
Latin America (Colombia, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Get a Discount on the purchase of this report @ https://www.coherentmarketinsights.com/insight/buy-now/4953

Reasons to Purchase this Report:

✔ Regional report analysis highlighting the consumption of products/services in a region also shows the factors that influence the market in each region.
✔ Reports provide opportunities and threats faced by suppliers in the U.S. Naloxone industry around the world.
✔ The report shows regions and sectors with the fastest growth potential.
✔ A competitive environment that includes market rankings of major companies, along with new product launches, partnerships, business expansions, and acquisitions.
✔ The report provides an extensive corporate profile consisting of company overviews, company insights, product benchmarks, and SWOT analysis for key market participants.
✔ This report provides the industry's current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.

📌Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd,
📞Phone: U.S.: +1-206-701-6702
📞U.K.: +44-020-8133-4027
📞JAPAN: +81-50-5539-1737
📞INDIA: +91-848-285-0837
✉ Email: sales@coherentmarketinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.